MRD in PAAD Adjuvant Therapy

NCT06867146 · tracked via the Priya Life Science China tracker

Sponsor

Peking Union Medical College Hospital

Phase

Not applicable

Started

2024-10-15

Last updated

2025-03-10

Condition(s) studied

The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant TherapyMolecular Residual DiseasePancreatic CancerAdjuvant Therapy

Investigational drug(s) / intervention(s)

Three-drug chemotherapy grouptwo-drug chemotherapy group

Three-drug chemotherapy group: Three-drug chemotherapy group, mFOLFIRINOX, including 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.

two-drug chemotherapy group: two-drug chemotherapy group, including gemcitabine-based combination regimens (predominately gemcitabine/nab-paclitaxel or gemcitabine/capecitabine)

Study summary

Our preliminary research has explored the detection efficacy of minimal residual disease (MRD) in pancreatic cancer. In patients with pancreatic cancer undergoing dual-agent adjuvant chemotherapy, the median recurrence-free survival (RFS) is approximately 13.9 months. Due to the high postoperative recurrence rate, short survival time, and intense systemic chemotherapy in pancreatic cancer patients, there is an urgent clinical need to more accurately identify which patients will benefit from adjuvant therapy. This study aims to evaluate the application value and guiding significance of peripheral blood MRD in the decision-making process for adjuvant treatment in patients with resected pancreatic cancer.

Eligibility

Sex

ALL

Min age

18 Years

Max age

70 Years

Healthy volunteers

Inclusion Criteria: * Here's the translated and polished version of your content: 1. Patients clinically diagnosed with pancreatic cancer, staged I-III (AJCC V8.0), who are scheduled to undergo curative surgery. 2. No restrictions on gender; age between 18 and 70 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status score: ≤2. 4. Expected survival time of ≥3 months. 5. Willingness to comply with the study protocol for testing, treatment, and follow-up; consent to provide necessary clinical, pathological, and follow-up data for the study; and agreement to use the research data for future studies and product development. 6. Voluntary participation in this clinical study, with an understanding of the study procedures and the ability to sign an informed consent form. Exclusion Criteria: 1. Patients who have had other malignancies within the five years prior to this study. 2. Patients who have received any antitumor treatment within six months prior to enrollment. 3. Patients with concomitant diseases that, in the investigator's judgment, pose a serious risk to patient safety or could affect the patient's ability to complete the study (such as poorly controlled hypertension, severe diabetes, thyroid disorders, psychiatric disorders, etc.), or any other conditions deemed unsuitable for participation.

Primary outcome measure(s)

DFS — up to 18 months
DFS refers to the length of time after treatment during which a patient remains free of any signs or symptoms of the disease. It is primarily used in cancer research to measure the effectiveness of treatments in preventing recurrence. Median follow-up time up to 18 months

Trial sites (1)

Facility	City	Region	Status
Peking Union Medical College Hospital	Beijing	Beijing Municipality

More Peking Union Medical College Hospital trials in China

Safety and Efficacy Study of PUMCH-E101 Injection in Subjects with RDH12 Retinopathy Recruiting

Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial Starting soon

Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer Recruiting

Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer Recruiting

Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement Recruiting

Other trials for the same condition

Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer Starting soon

NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor Recruiting

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors Recruiting

Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer Recruiting

CAR-NK Cells (CL-NK-003) in Pancreatic Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06867146 on ClinicalTrials.gov ↗ ← All trials in China